Segment disclosures

Company overview

ALLERGAN PLC

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

214 dimension combinations 788 retained observations 7 reported periods Partial retained history

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Operating Segments · International

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31691400000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30835100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-302484300000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-06-301649200000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2018-01-01 – 2018-09-302634500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Operating Segments · International · Asia Pacific Middle East And Africa

Consolidation Items · Statement Business Segments · Statement Geographical

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:StatementGeographicalAxis=agn:AsiaPacificMiddleEastAndAfricaMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-311075100000 USD20200218Open filing evidence
2018-01-01 – 2018-12-311089900000 USD20200218Open filing evidence

Operating Segments · International · Latin America And Canada

Consolidation Items · Statement Business Segments · Statement Geographical

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:StatementGeographicalAxis=agn:LatinAmericaAndCanadaMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31772900000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31862400000 USD20200218Open filing evidence

Operating Segments · International · Other Geographic Area

Consolidation Items · Statement Business Segments · Statement Geographical

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:StatementGeographicalAxis=agn:OtherGeographicAreaMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-3182300000 USD20200218Open filing evidence
2018-01-01 – 2018-12-3169800000 USD20200218Open filing evidence

Operating Segments · International · Europe

Consolidation Items · Statement Business Segments · Statement Geographical

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:StatementGeographicalAxis=srt:EuropeMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-311471700000 USD20200218Open filing evidence
2018-01-01 – 2018-12-311482600000 USD20200218Open filing evidence

Operating Segments · US General Medicine

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-311320500000 USD20200507Open filing evidence
2019-07-01 – 2019-09-301518600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-304224200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-06-302705600000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2018-01-01 – 2018-09-303925000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Operating Segments · US Specialized Therapeutics

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-311541500000 USD20200507Open filing evidence
2019-07-01 – 2019-09-301670800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-304998800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-06-303328000000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2018-01-01 – 2018-09-305111500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Aczone · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:AczoneMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2018-01-01 – 2018-12-31400000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30300000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Aczone · Operating Segments · US Specialized Therapeutics

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:AczoneMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-313000000 USD20200507Open filing evidence
2019-07-01 – 2019-09-303400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-306800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-3155100000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3054500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Alloderm · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:AllodermMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-311700000 USD20200507Open filing evidence
2019-07-01 – 2019-09-302100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-305900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-318000000 USD20200218Open filing evidence
2018-01-01 – 2018-09-305500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Alloderm · Operating Segments · US Specialized Therapeutics

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:AllodermMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31102100000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3095000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30291200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31407300000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30312400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Alphagan And Combigan · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:AlphaganAndCombiganMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3136900000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3040400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30118900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31176000000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30129300000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Alphagan And Combigan · Operating Segments · US Specialized Therapeutics

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:AlphaganAndCombiganMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3181600000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3090900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30265500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31375400000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30277700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Armour Thyroid · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:ArmourThyroidMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3146300000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3054400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30161100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31198800000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30145400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Avycaz · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:AvycazMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3111800000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3029600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3086000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-3194600000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3070000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Botox · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:BotoxMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31203700000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30259500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30775400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-311031600000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30777100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Botox · Operating Segments · US Specialized Therapeutics

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:BotoxMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31608500000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30669200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-301995700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-312545800000 USD20200218Open filing evidence
2018-01-01 – 2018-09-301854400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Breast Implants · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:BreastImplantsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-315200000 USD20200507Open filing evidence
2019-07-01 – 2019-09-305700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30-14500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31130100000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30119600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Breast Implants · Operating Segments · US Specialized Therapeutics

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:BreastImplantsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3140100000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3058500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30187300000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31263000000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30194800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Bystolic And Byvalson · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:BystolicAndByvalsonMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31500000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-301500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-312000000 USD20200218Open filing evidence
2018-01-01 – 2018-09-301600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Bystolic And Byvalson · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:BystolicAndByvalsonMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31129800000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30152200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30431000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31583800000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30432100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Canasa And Salofalk · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:CanasaAndSalofalkMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-314000000 USD20200507Open filing evidence
2019-07-01 – 2019-09-304400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3012100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-3117600000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3013100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Canasa And Salofalk · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:CanasaAndSalofalkMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-317200000 USD20200507Open filing evidence
2019-07-01 – 2019-09-305800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3024000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31169200000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30130400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Carafate And Sulcrate · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:CarafateAndSulcrateMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-311000000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-302100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-312800000 USD20200218Open filing evidence
2018-01-01 – 2018-09-302100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Carafate And Sulcrate · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:CarafateAndSulcrateMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3119000000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3055100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30165600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31217800000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30163700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Coolsculpting Consumables · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:CoolsculptingConsumablesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-318800000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3021600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3059700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-3164200000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3040800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Coolsculpting Consumables · Operating Segments · US Specialized Therapeutics

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:CoolsculptingConsumablesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3122700000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3040400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30148900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31235300000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30180800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Coolsculpting Systems And Add On Applicators · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:CoolsculptingSystemsAndAddOnApplicatorsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-311400000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3011400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3033600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-3143300000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3021800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Coolsculpting Systems And Add On Applicators · Operating Segments · US Specialized Therapeutics

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:CoolsculptingSystemsAndAddOnApplicatorsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3136200000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3012600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3045900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31126300000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3099500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Dalvance · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:DalvanceMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-313100000 USD20200507Open filing evidence
2019-07-01 – 2019-09-301400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-303600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-312300000 USD20200218Open filing evidence
2018-01-01 – 2018-09-301300000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Dalvance · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:DalvanceMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3123000000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3023200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3055500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-3156100000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3038800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Delzicol And Asacol HD · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:DelzicolAndAsacolHDMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-317700000 USD20200507Open filing evidence
2019-07-01 – 2019-09-307200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3027200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-3145700000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3035000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Delzicol And Asacol HD · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:DelzicolAndAsacolHDMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-312600000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3011900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3068200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31130800000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30102900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Eye Drops · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:EyeDropsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3150900000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3063800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30176500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31279700000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30208000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Eye Drops · Operating Segments · US Specialized Therapeutics

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:EyeDropsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3166500000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3062000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30169200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31202700000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30154800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Juvederm Collection · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:JuvedermCollectionMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31113100000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30144700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30475200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31614800000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30440800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Juvederm Collection · Operating Segments · US Specialized Therapeutics

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:JuvedermCollectionMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31107500000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30134800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30421100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31548200000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30389800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Kybella And Belkyra · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:KybellaAndBelkyraMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31100000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30300000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-302500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-316300000 USD20200218Open filing evidence
2018-01-01 – 2018-09-305300000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Kybella And Belkyra · Operating Segments · US Specialized Therapeutics

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:KybellaAndBelkyraMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-315300000 USD20200507Open filing evidence
2019-07-01 – 2019-09-305300000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3021100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-3131800000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3024600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Liletta · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:LilettaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3123100000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3019900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3056600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-3150900000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3036300000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Linzess And Constella · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:LinzessAndConstellaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-317100000 USD20200507Open filing evidence
2019-07-01 – 2019-09-306700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3017000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-3124100000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3017700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Linzess And Constella · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:LinzessAndConstellaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31172200000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30214700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30572000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31761100000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30555900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Lo Loestrin Fe · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:LoLoestrinFeMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31109800000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30161400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30432700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31527700000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30383900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Lumigan And Ganfort · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:LumiganAndGanfortMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3180700000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3089700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30265200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31392600000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30295700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Lumigan And Ganfort · Operating Segments · US Specialized Therapeutics

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:LumiganAndGanfortMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3163000000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3067500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30187300000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31291800000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30217800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Namenda · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:NamendaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-312900000 USD20200507Open filing evidence
2019-07-01 – 2019-09-304000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3019600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-3171000000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3060300000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Namzaric · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:NamzaricMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3117800000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3022400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3068400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31115800000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3093200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Other · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:OtherMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3180700000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3089900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30257100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31380200000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30291100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Other · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:OtherMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31188600000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30203100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30591000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31749300000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30568200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Other · Operating Segments · US Specialized Therapeutics

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:OtherMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3156600000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3069400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30200600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31308900000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30235300000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Ozurdex · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:OzurdexMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3163800000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3063800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30207900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31187700000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30158100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Ozurdex · Operating Segments · US Specialized Therapeutics

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:OzurdexMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3129900000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3033700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3093900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31111000000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3081700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Rapaflo · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:RapafloMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-311100000 USD20200507Open filing evidence
2019-07-01 – 2019-09-301500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-303500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-316400000 USD20200218Open filing evidence
2018-01-01 – 2018-09-304600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Rapaflo · Operating Segments · US Specialized Therapeutics

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:RapafloMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-311400000 USD20200507Open filing evidence
2019-07-01 – 2019-09-305200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3021500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-3181900000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3063000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Restasis · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:RestasisMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3111300000 USD20200507Open filing evidence
2019-07-01 – 2019-09-309200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3031500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-3164500000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3047900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Restasis · Operating Segments · US Specialized Therapeutics

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:RestasisMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31278600000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30286800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30829400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-311197000000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30872000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Saphris · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:SaphrisMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3131000000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3034500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3099000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31139700000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30102900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Savella · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:SavellaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3119300000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3024000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3067000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-3185000000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3061400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Skin Care · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:SkinCareMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-312800000 USD20200507Open filing evidence
2019-07-01 – 2019-09-304000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3010400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-3115200000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3011600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Skin Care · Operating Segments · US Specialized Therapeutics

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:SkinCareMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3138500000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3036100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30113400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31138800000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3098400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Teflaro · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:TeflaroMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-311500000 USD20200507Open filing evidence
2019-07-01 – 2019-09-302100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-302300000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31300000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Teflaro · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:TeflaroMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3135000000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3038400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30108900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31128000000 USD20200218Open filing evidence
2018-01-01 – 2018-09-3098000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Ubrelvy · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:UbrelvyMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3111100000 USD20200507Open filing evidence

Viberzi · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:ViberziMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31400000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-301200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-311300000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Viberzi · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:ViberziMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3137300000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3050100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30138100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31176500000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30127600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Viibryd Fetzima · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:ViibrydFetzimaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-313500000 USD20200507Open filing evidence
2019-07-01 – 2019-09-303000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-307800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-317200000 USD20200218Open filing evidence
2018-01-01 – 2018-09-304900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Viibryd Fetzima · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:ViibrydFetzimaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3189800000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30105100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30297900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31342400000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30246900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Vraylar · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:VraylarMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31277300000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30234600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30574400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31487100000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30336600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Zenpep · Operating Segments · International

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:ZenpepMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31400000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31400000 USD20200218Open filing evidence

Zenpep · Operating Segments · US General Medicine

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=agn:ZenpepMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3165600000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3074200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30207200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-12-31237300000 USD20200218Open filing evidence
2018-01-01 – 2018-09-30170500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Asia Pacific Middle East And Africa · Operating Segments · International

Statement Geographical · Consolidation Items · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=agn:AsiaPacificMiddleEastAndAfricaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31182800000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30266900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30779100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-04-01 – 2019-06-30261500000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30512200000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-31250700000 USD20200507Open filing evidence
2018-07-01 – 2018-09-30272400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30796800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Latin America And Canada · Operating Segments · International

Statement Geographical · Consolidation Items · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=agn:LatinAmericaAndCanadaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31161800000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30199900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-30560200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-04-01 – 2019-06-30182100000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30360300000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-31178200000 USD20200507Open filing evidence
2018-07-01 – 2018-09-30203300000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30646200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Other Geographic Area · Operating Segments · International

Statement Geographical · Consolidation Items · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=agn:OtherGeographicAreaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3123800000 USD20200507Open filing evidence
2019-07-01 – 2019-09-3021800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-3057900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-04-01 – 2019-06-3017900000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3036100000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3118200000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3016100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-3050000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

Europe · Operating Segments · International

Statement Geographical · Consolidation Items · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=srt:EuropeMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31323000000 USD20200507Open filing evidence
2019-07-01 – 2019-09-30346500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-01-01 – 2019-09-301087100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2019-04-01 – 2019-06-30386200000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30740600000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-31354400000 USD20200507Open filing evidence
2018-07-01 – 2018-09-30329800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-301141500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

International · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-313402000000 USD20200218Open filing evidence
2019-04-01 – 2019-06-30847700000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-31801500000 USD20200507Open filing evidence
2018-01-01 – 2018-12-313504700000 USD20200218Open filing evidence
2018-07-01 – 2018-09-30821600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

International · Operating Segments · Aczone

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:AczoneMember
PeriodValueUnitFiledEvidence
2018-01-01 – 2018-12-31400000 USD20190215Open filing evidence

International · Operating Segments · Alloderm

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:AllodermMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-317900000 USD20200218Open filing evidence
2018-01-01 – 2018-12-318000000 USD20190215Open filing evidence

International · Operating Segments · Alphagan And Combigan

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:AlphaganAndCombiganMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31162000000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31176000000 USD20190215Open filing evidence

International · Operating Segments · Botox

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:BotoxMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-311060800000 USD20200218Open filing evidence
2018-01-01 – 2018-12-311031600000 USD20190215Open filing evidence

International · Operating Segments · Breast Implants

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:BreastImplantsMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31600000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31130100000 USD20190215Open filing evidence

International · Operating Segments · Bystolic And Byvalson

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:BystolicAndByvalsonMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-312100000 USD20200218Open filing evidence
2018-01-01 – 2018-12-312000000 USD20190215Open filing evidence

International · Operating Segments · Canasa And Salofalk

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:CanasaAndSalofalkMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-3116800000 USD20200218Open filing evidence
2018-01-01 – 2018-12-3117600000 USD20190215Open filing evidence

International · Operating Segments · Carafate And Sulcrate

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:CarafateAndSulcrateMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-313000000 USD20200218Open filing evidence
2018-01-01 – 2018-12-312800000 USD20190215Open filing evidence

International · Operating Segments · Coolsculpting Consumables

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:CoolsculptingConsumablesMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-3176300000 USD20200218Open filing evidence
2018-01-01 – 2018-12-3164200000 USD20190215Open filing evidence

International · Operating Segments · Coolsculpting Systems And Add On Applicators

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:CoolsculptingSystemsAndAddOnApplicatorsMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-3142400000 USD20200218Open filing evidence
2018-01-01 – 2018-12-3143300000 USD20190215Open filing evidence

International · Operating Segments · Dalvance

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:DalvanceMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-316000000 USD20200218Open filing evidence
2018-01-01 – 2018-12-312300000 USD20190215Open filing evidence

International · Operating Segments · Delzicol And Asacol HD

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:DelzicolAndAsacolHDMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-3136100000 USD20200218Open filing evidence
2018-01-01 – 2018-12-3145700000 USD20190215Open filing evidence

International · Operating Segments · Eye Drops

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:EyeDropsMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31235800000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31279700000 USD20190215Open filing evidence

International · Operating Segments · Juvederm Collection

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:JuvedermCollectionMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31656100000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31614800000 USD20190215Open filing evidence

International · Operating Segments · Kybella And Belkyra

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:KybellaAndBelkyraMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-313300000 USD20200218Open filing evidence
2018-01-01 – 2018-12-316300000 USD20190215Open filing evidence

International · Operating Segments · Linzess And Constella

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:LinzessAndConstellaMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-3123800000 USD20200218Open filing evidence
2018-01-01 – 2018-12-3124100000 USD20190215Open filing evidence

International · Operating Segments · Lumigan And Ganfort

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:LumiganAndGanfortMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31360800000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31392600000 USD20190215Open filing evidence

International · Operating Segments · Other

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:OtherMember
PeriodValueUnitFiledEvidence
2018-01-01 – 2018-12-31379500000 USD20190215Open filing evidence

International · Operating Segments · Other Products Revenues

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:OtherProductsRevenuesMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31342600000 USD20200218Open filing evidence

International · Operating Segments · Ozurdex

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:OzurdexMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31274600000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31187700000 USD20190215Open filing evidence

International · Operating Segments · Rapaflo

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:RapafloMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-316000000 USD20200218Open filing evidence
2018-01-01 – 2018-12-316400000 USD20190215Open filing evidence

International · Operating Segments · Restasis

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:RestasisMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-3150200000 USD20200218Open filing evidence
2018-01-01 – 2018-12-3164500000 USD20190215Open filing evidence

International · Operating Segments · Skin Care

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:SkinCareMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-3114600000 USD20200218Open filing evidence
2018-01-01 – 2018-12-3115200000 USD20190215Open filing evidence

International · Operating Segments · Tazorac

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:TazoracMember
PeriodValueUnitFiledEvidence
2018-01-01 – 2018-12-31700000 USD20190215Open filing evidence

International · Operating Segments · Teflaro

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:TeflaroMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-316000000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31300000 USD20190215Open filing evidence

International · Operating Segments · Viberzi

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:ViberziMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-311600000 USD20200218Open filing evidence
2018-01-01 – 2018-12-311300000 USD20190215Open filing evidence

International · Operating Segments · Viibryd Fetzima

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:ViibrydFetzimaMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-3111400000 USD20200218Open filing evidence
2018-01-01 – 2018-12-317200000 USD20190215Open filing evidence

International · Operating Segments · Zenpep

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:ZenpepMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-311200000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31400000 USD20190215Open filing evidence

International · Aczone · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:AczoneMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2018-07-01 – 2018-09-30100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30300000 USD20181031Open filing evidence

International · Alloderm · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:AllodermMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-302200000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-303800000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-311600000 USD20200507Open filing evidence
2018-07-01 – 2018-09-301000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-305500000 USD20181031Open filing evidence

International · Alphagan And Combigan · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:AlphaganAndCombiganMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3040900000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3078500000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3137600000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3040500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30129300000 USD20181031Open filing evidence

International · Botox · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:BotoxMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-30274600000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30515900000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-31241300000 USD20200507Open filing evidence
2018-07-01 – 2018-09-30256300000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30777100000 USD20181031Open filing evidence

International · Breast Implants · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:BreastImplantsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-30-31400000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30-20200000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3111200000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3035600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30119600000 USD20181031Open filing evidence

International · Bystolic And Byvalson · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:BystolicAndByvalsonMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-30500000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30900000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-31400000 USD20200507Open filing evidence
2018-07-01 – 2018-09-30500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-301600000 USD20181031Open filing evidence

International · Canasa And Salofalk · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:CanasaAndSalofalkMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-304100000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-307700000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-313600000 USD20200507Open filing evidence
2018-07-01 – 2018-09-304400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-3013100000 USD20181031Open filing evidence

International · Carafate And Sulcrate · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:CarafateAndSulcrateMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-30700000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-301300000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-31600000 USD20200507Open filing evidence
2018-07-01 – 2018-09-30700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-302100000 USD20181031Open filing evidence

International · Coolsculpting Consumables · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:CoolsculptingConsumablesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3020300000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3038100000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3117800000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3014200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-3040800000 USD20181031Open filing evidence

International · Coolsculpting Systems And Add On Applicators · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:CoolsculptingSystemsAndAddOnApplicatorsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3011600000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3022200000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3110600000 USD20200507Open filing evidence
2018-07-01 – 2018-09-308300000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-3021800000 USD20181031Open filing evidence

International · Dalvance · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:DalvanceMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-302200000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-302200000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2018-01-01 – 2018-09-301300000 USD20181031Open filing evidence

International · Delzicol And Asacol HD · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:DelzicolAndAsacolHDMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-309700000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3020000000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3110300000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3010900000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-3035000000 USD20181031Open filing evidence

International · Eye Drops · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:EyeDropsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3057300000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30112700000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3155400000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3066800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30208000000 USD20181031Open filing evidence

International · Juvederm Collection · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:JuvedermCollectionMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-30172700000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30330500000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-31157800000 USD20200507Open filing evidence
2018-07-01 – 2018-09-30138600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30440800000 USD20181031Open filing evidence

International · Kybella And Belkyra · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:KybellaAndBelkyraMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-30600000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-302200000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-311600000 USD20200507Open filing evidence
2018-07-01 – 2018-09-301600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-305300000 USD20181031Open filing evidence

International · Latisse · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:LatisseMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2018-07-01 – 2018-09-302000000 USD20181031Open filing evidence
2018-01-01 – 2018-09-306300000 USD20181031Open filing evidence

International · Linzess And Constella · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:LinzessAndConstellaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-304800000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3010300000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-315500000 USD20200507Open filing evidence
2018-07-01 – 2018-09-305700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-3017700000 USD20181031Open filing evidence

International · Lumigan And Ganfort · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:LumiganAndGanfortMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3090400000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30175500000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3185100000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3094800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30295700000 USD20181031Open filing evidence

International · Other · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:OtherMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3085500000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30167200000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3181700000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3094600000 RestatedUSD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30290500000 USD20181031Open filing evidence

International · Ozurdex · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:OzurdexMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3081000000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30144100000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3163100000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3025800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30158100000 USD20181031Open filing evidence

International · Rapaflo · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:RapafloMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-301400000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-302000000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-31600000 USD20200507Open filing evidence
2018-07-01 – 2018-09-301800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-304600000 USD20181031Open filing evidence

International · Restasis · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:RestasisMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3011900000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3022300000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3110400000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3013600000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-3047900000 USD20181031Open filing evidence

International · Skin Care · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:SkinCareMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-303700000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-306400000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-312700000 USD20200507Open filing evidence
2018-07-01 – 2018-09-303700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

International · Skin Medica · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:SkinMedicaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2018-07-01 – 2018-09-301700000 USD20181031Open filing evidence
2018-01-01 – 2018-09-305300000 USD20181031Open filing evidence

International · Tazorac · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:TazoracMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2018-07-01 – 2018-09-30200000 USD20181031Open filing evidence
2018-01-01 – 2018-09-30600000 USD20181031Open filing evidence

International · Teflaro · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:TeflaroMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-06-30200000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-31200000 USD20200507Open filing evidence
2018-01-01 – 2018-09-30600000 USD20181031Open filing evidence

International · Viberzi · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:ViberziMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-30300000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30600000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-31300000 USD20200507Open filing evidence
2018-07-01 – 2018-09-30300000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30700000 USD20181031Open filing evidence

International · Viibryd Fetzima · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:InternationalMember;srt:ProductOrServiceAxis=agn:ViibrydFetzimaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-302700000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-304800000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-312100000 USD20200507Open filing evidence
2018-07-01 – 2018-09-301800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-304900000 USD20181031Open filing evidence

US General Medicine · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-315834900000 USD20200218Open filing evidence
2019-04-01 – 2019-06-301455700000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-311249900000 USD20200507Open filing evidence
2018-01-01 – 2018-12-315322900000 USD20200218Open filing evidence
2018-07-01 – 2018-09-301381300000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

US General Medicine · Operating Segments · Armour Thyroid

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:ArmourThyroidMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31218500000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31198800000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Avycaz

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:AvycazMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31116700000 USD20200218Open filing evidence
2018-01-01 – 2018-12-3194600000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Bystolic And Byvalson

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:BystolicAndByvalsonMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31600600000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31583800000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Canasa And Salofalk

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:CanasaAndSalofalkMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-3131500000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31169200000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Carafate And Sulcrate

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:CarafateAndSulcrateMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31212500000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31217800000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Dalvance

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:DalvanceMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-3181900000 USD20200218Open filing evidence
2018-01-01 – 2018-12-3156100000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Delzicol And Asacol HD

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:DelzicolAndAsacolHDMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-3176700000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31130800000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Estrace Cream

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:EstraceCreamMember
PeriodValueUnitFiledEvidence
2018-01-01 – 2018-12-3149000000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Liletta

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:LilettaMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-3179100000 USD20200218Open filing evidence
2018-01-01 – 2018-12-3150900000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Linzess And Constella

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:LinzessAndConstellaMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31803200000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31761100000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Lo Loestrin Fe

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:LoLoestrinFeMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31588900000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31527700000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Minastrin Fe

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:MinastrinFeMember
PeriodValueUnitFiledEvidence
2018-01-01 – 2018-12-319500000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Namenda

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:NamendaMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-3122800000 USD20200218Open filing evidence
2018-01-01 – 2018-12-3171000000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Namzaric

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:NamzaricMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-3188600000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31115800000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Other

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:OtherMember
PeriodValueUnitFiledEvidence
2018-01-01 – 2018-12-31690800000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Other Products Revenues

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:OtherProductsRevenuesMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31797600000 USD20200218Open filing evidence

US General Medicine · Operating Segments · Saphris

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:SaphrisMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31135300000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31139700000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Savella

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:SavellaMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-3188500000 USD20200218Open filing evidence
2018-01-01 – 2018-12-3185000000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Teflaro

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:TeflaroMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31147000000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31128000000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Viberzi

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:ViberziMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31187900000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31176500000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Viibryd Fetzima

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:ViibrydFetzimaMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31412100000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31342400000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Vraylar

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:VraylarMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31857500000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31487100000 USD20190215Open filing evidence

US General Medicine · Operating Segments · Zenpep

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:ZenpepMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31288000000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31237300000 USD20190215Open filing evidence

US General Medicine · Armour Thyroid · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:ArmourThyroidMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3056700000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30106700000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3150000000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3048000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30145400000 USD20181031Open filing evidence

US General Medicine · Avycaz · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:AvycazMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3026700000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3056400000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3129700000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3024700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-3070000000 USD20181031Open filing evidence

US General Medicine · Bystolic And Byvalson · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:BystolicAndByvalsonMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-30150500000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30278800000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-31128300000 USD20200507Open filing evidence
2018-07-01 – 2018-09-30151200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30432100000 USD20181031Open filing evidence

US General Medicine · Canasa And Salofalk · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:CanasaAndSalofalkMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-308000000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3018200000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3110200000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3046800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30130400000 USD20181031Open filing evidence

US General Medicine · Carafate And Sulcrate · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:CarafateAndSulcrateMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3056200000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30110500000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3154300000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3053400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30163700000 USD20181031Open filing evidence

US General Medicine · Dalvance · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:DalvanceMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3020300000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3032300000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3112000000 USD20200507Open filing evidence
2018-07-01 – 2018-09-309200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-3038800000 USD20181031Open filing evidence

US General Medicine · Delzicol And Asacol HD · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:DelzicolAndAsacolHDMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3031600000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3056300000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3124700000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3032100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30102900000 USD20181031Open filing evidence

US General Medicine · Estrace Cream · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:EstraceCreamMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2018-07-01 – 2018-09-3014800000 USD20181031Open filing evidence
2018-01-01 – 2018-09-3034300000 USD20181031Open filing evidence

US General Medicine · Lexapro · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:LexaproMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2018-07-01 – 2018-09-3015600000 USD20181031Open filing evidence
2018-01-01 – 2018-09-3044800000 USD20181031Open filing evidence

US General Medicine · Liletta · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:LilettaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3021900000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3036700000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3114800000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3012700000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-3036300000 USD20181031Open filing evidence

US General Medicine · Linzess And Constella · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:LinzessAndConstellaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-30196000000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30357300000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-31161300000 USD20200507Open filing evidence
2018-07-01 – 2018-09-30204800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30555900000 USD20181031Open filing evidence

US General Medicine · Lo Loestrin Fe · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:LoLoestrinFeMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-30145500000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30271300000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-31125800000 USD20200507Open filing evidence
2018-07-01 – 2018-09-30141500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30383900000 USD20181031Open filing evidence

US General Medicine · Minastrin Fe · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:MinastrinFeMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2018-07-01 – 2018-09-30600000 USD20181031Open filing evidence
2018-01-01 – 2018-09-306600000 USD20181031Open filing evidence

US General Medicine · Namenda · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:NamendaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-306100000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3015600000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-319500000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3016300000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

US General Medicine · Namenda Xr · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:NamendaXrMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2018-07-01 – 2018-09-3016200000 USD20181031Open filing evidence
2018-01-01 – 2018-09-3060100000 USD20181031Open filing evidence

US General Medicine · Namzaric · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:NamzaricMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3022600000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3046000000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3123400000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3028000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-3093200000 USD20181031Open filing evidence

US General Medicine · Other · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:OtherMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-30197000000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30387900000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-31190900000 USD20200507Open filing evidence
2018-07-01 – 2018-09-30185000000 RestatedUSD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30482700000 USD20181031Open filing evidence

US General Medicine · Saphris · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:SaphrisMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3032600000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3064500000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3131900000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3036400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30102900000 USD20181031Open filing evidence

US General Medicine · Savella · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:SavellaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3022300000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3043000000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3120700000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3022400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-3061400000 USD20181031Open filing evidence

US General Medicine · Teflaro · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:TeflaroMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3037000000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3070500000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3133500000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3033400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-3098000000 USD20181031Open filing evidence

US General Medicine · Viberzi · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:ViberziMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3050800000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3088000000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3137200000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3046800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30127600000 USD20181031Open filing evidence

US General Medicine · Viibryd Fetzima · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:ViibrydFetzimaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-30107800000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30192800000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3185000000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3088500000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30246900000 USD20181031Open filing evidence

US General Medicine · Vraylar · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:VraylarMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-30196100000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30339800000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-31143700000 USD20200507Open filing evidence
2018-07-01 – 2018-09-30138000000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30336600000 USD20181031Open filing evidence

US General Medicine · Zenpep · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USGeneralMedicineMember;srt:ProductOrServiceAxis=agn:ZenpepMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3070000000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30133000000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3163000000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3062100000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30170500000 USD20181031Open filing evidence

US Specialized Therapeutics · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-316820000000 USD20200218Open filing evidence
2019-04-01 – 2019-06-301785100000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-311542900000 USD20200507Open filing evidence
2018-01-01 – 2018-12-316920300000 USD20200218Open filing evidence
2018-07-01 – 2018-09-301706200000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence

US Specialized Therapeutics · Operating Segments · Aczone

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:AczoneMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-319300000 USD20200218Open filing evidence
2018-01-01 – 2018-12-3155100000 USD20190215Open filing evidence

US Specialized Therapeutics · Operating Segments · Alloderm

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:AllodermMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31395900000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31407300000 USD20190215Open filing evidence

US Specialized Therapeutics · Operating Segments · Alphagan And Combigan

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:AlphaganAndCombiganMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31360000000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31375400000 USD20190215Open filing evidence

US Specialized Therapeutics · Operating Segments · Botox

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:BotoxMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-312730500000 USD20200218Open filing evidence
2018-01-01 – 2018-12-312545800000 USD20190215Open filing evidence

US Specialized Therapeutics · Operating Segments · Breast Implants

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:BreastImplantsMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31254400000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31263000000 USD20190215Open filing evidence

US Specialized Therapeutics · Operating Segments · Coolsculpting Consumables

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:CoolsculptingConsumablesMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31185300000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31235300000 USD20190215Open filing evidence

US Specialized Therapeutics · Operating Segments · Coolsculpting Systems And Add On Applicators

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:CoolsculptingSystemsAndAddOnApplicatorsMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-3162800000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31126300000 USD20190215Open filing evidence

US Specialized Therapeutics · Operating Segments · Eye Drops

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:EyeDropsMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31230400000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31202700000 USD20190215Open filing evidence

US Specialized Therapeutics · Operating Segments · Juvederm Collection

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:JuvedermCollectionMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31587500000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31548200000 USD20190215Open filing evidence

US Specialized Therapeutics · Operating Segments · Kybella And Belkyra

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:KybellaAndBelkyraMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-3127400000 USD20200218Open filing evidence
2018-01-01 – 2018-12-3131800000 USD20190215Open filing evidence

US Specialized Therapeutics · Operating Segments · Lumigan And Ganfort

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:LumiganAndGanfortMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31269200000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31291800000 USD20190215Open filing evidence

US Specialized Therapeutics · Operating Segments · Other

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:OtherMember
PeriodValueUnitFiledEvidence
2018-01-01 – 2018-12-31283500000 USD20190215Open filing evidence

US Specialized Therapeutics · Operating Segments · Other Products Revenues

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:OtherProductsRevenuesMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31261900000 USD20200218Open filing evidence

US Specialized Therapeutics · Operating Segments · Ozurdex

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:OzurdexMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31125500000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31111000000 USD20190215Open filing evidence

US Specialized Therapeutics · Operating Segments · Rapaflo

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:RapafloMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-3123500000 USD20200218Open filing evidence
2018-01-01 – 2018-12-3181900000 USD20190215Open filing evidence

US Specialized Therapeutics · Operating Segments · Restasis

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:RestasisMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-311138400000 USD20200218Open filing evidence
2018-01-01 – 2018-12-311197000000 USD20190215Open filing evidence

US Specialized Therapeutics · Operating Segments · Skin Care

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:SkinCareMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-12-31158000000 USD20200218Open filing evidence
2018-01-01 – 2018-12-31138800000 USD20190215Open filing evidence

US Specialized Therapeutics · Operating Segments · Tazorac

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=agn:TazoracMember
PeriodValueUnitFiledEvidence
2018-01-01 – 2018-12-3125400000 USD20190215Open filing evidence

US Specialized Therapeutics · Aczone · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ProductOrServiceAxis=agn:AczoneMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-301800000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-303400000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-311600000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3017400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-3054500000 USD20181031Open filing evidence

US Specialized Therapeutics · Alloderm · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ProductOrServiceAxis=agn:AllodermMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-30101200000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30196200000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3195000000 USD20200507Open filing evidence
2018-07-01 – 2018-09-30105800000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30312400000 USD20181031Open filing evidence

US Specialized Therapeutics · Alphagan And Combigan · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ProductOrServiceAxis=agn:AlphaganAndCombiganMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3091600000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30174600000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3183000000 USD20200507Open filing evidence
2018-07-01 – 2018-09-3095400000 USD2019-11-05 · 22:00:24.000ZOpen filing evidence
2018-01-01 – 2018-09-30277700000 USD20181031Open filing evidence

US Specialized Therapeutics · Botox · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ProductOrServiceAxis=agn:BotoxMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-30699400000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-301326500000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-31627100000 USD20200507Open filing evidence

US Specialized Therapeutics · Breast Implants · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ProductOrServiceAxis=agn:BreastImplantsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3067600000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30128800000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3161200000 USD20200507Open filing evidence

US Specialized Therapeutics · Coolsculpting Consumables · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ProductOrServiceAxis=agn:CoolsculptingConsumablesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3060700000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30108500000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3147800000 USD20200507Open filing evidence

US Specialized Therapeutics · Coolsculpting Systems And Add On Applicators · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ProductOrServiceAxis=agn:CoolsculptingSystemsAndAddOnApplicatorsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3018200000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3033300000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3115100000 USD20200507Open filing evidence

US Specialized Therapeutics · Eye Drops · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ProductOrServiceAxis=agn:EyeDropsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3057800000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30107200000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3149400000 USD20200507Open filing evidence

US Specialized Therapeutics · Juvederm Collection · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ProductOrServiceAxis=agn:JuvedermCollectionMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-30156600000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30286300000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-31129700000 USD20200507Open filing evidence

US Specialized Therapeutics · Kybella And Belkyra · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ProductOrServiceAxis=agn:KybellaAndBelkyraMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-308500000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3015800000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-317300000 USD20200507Open filing evidence

US Specialized Therapeutics · Lumigan And Ganfort · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ProductOrServiceAxis=agn:LumiganAndGanfortMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3062100000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30119800000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3157700000 USD20200507Open filing evidence

US Specialized Therapeutics · Other · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ProductOrServiceAxis=agn:OtherMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3071700000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30131200000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3159500000 USD20200507Open filing evidence

US Specialized Therapeutics · Ozurdex · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ProductOrServiceAxis=agn:OzurdexMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3029900000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3060200000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3130300000 USD20200507Open filing evidence

US Specialized Therapeutics · Rapaflo · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ProductOrServiceAxis=agn:RapafloMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-304500000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3016300000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3111800000 USD20200507Open filing evidence

US Specialized Therapeutics · Restasis · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ProductOrServiceAxis=agn:RestasisMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-30310900000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-30542600000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-31231700000 USD20200507Open filing evidence

US Specialized Therapeutics · Skin Care · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=agn:USSpecializedTherapeuticsMember;srt:ProductOrServiceAxis=agn:SkinCareMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3042600000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-06-3077300000 USD2019-08-08 · 21:29:12.000ZOpen filing evidence
2019-01-01 – 2019-03-3134700000 USD20200507Open filing evidence